Atom | NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

Funder: National Institutes of Health

Due Dates: January 26, 2026 (Letter of Intent) | February 26, 2026 (Full Application) | January 26, 2027 (Letter of Intent) | February 26, 2027 (Full Application)

Funding Amounts: Up to $3,500,000 total costs per project (max 3 years); recommended not to exceed $1,166,667/year; up to $50,000 additional for Technical and Business Assistance (TABA)

Summary: Supports small businesses in bridging the funding gap between SBIR Phase II and commercialization for heart, lung, blood, and sleep disorder technologies, with a focus on regulatory approval and investor partnerships.

Key Information: Applicants must secure independent third-party investor funds equal to or exceeding the requested NHLBI funds; only U.S. small businesses are eligible.

NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

Sign in to see full grant listing